Although immune checkpoint inhibitors appear promising for lung cancer treatment, not all lung cancer patients respond to immune checkpoint inhibitors against PD-1 and CTLA-4, possibly because of their complexity and limitations in their tumor immunity.30 This evidence concerns the gene PDCD1 and neoplasm.